In vitro synergic antifungal effect of MUC7 12-mer with histatin-5 12-mer or miconazole

Journal of Antimicrobial Chemotherapy

Volumn 53, Issue 5, 2004, Pages 750-758

  Wei, Guo Xian ^a   Bobek, Libuse A ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

Antimicrobial peptides; Chequerboard assay; Combination; Haemolysis; Salivary mucin

Indexed keywords

ALANYLLYSYLARGINYLHISTIDYLHISTIDYLGLYCYLTYROSILYLLYSYLARGINYLLYSYLPHENYLALANYLHISTIDINE; AMPHOTERICIN B; ARGINYLLYSYLSERYLTYROSILYLLYSYLCYSTYLHISTIDINYLLYSYLARGINYLCYSTYLARGININE; HISTATIN; MICONAZOLE; MUCIN 7; POLYPEPTIDE ANTIBIOTIC AGENT; UNCLASSIFIED DRUG;

ANTIFUNGAL ACTIVITY; ARTICLE; CANDIDA ALBICANS; CONCENTRATION RESPONSE; CONTROLLED STUDY; CRYPTOCOCCUS NEOFORMANS; CULTURE MEDIUM; DILUTION; DRUG EXPOSURE; DRUG POTENTIATION; ERYTHROCYTE; FUNGAL STRAIN; HEMOLYSIS; HUMAN; HUMAN CELL; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN;

ANTIFUNGAL AGENTS; CANDIDA ALBICANS; CRYPTOCOCCUS NEOFORMANS; CULTURE MEDIA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; ERYTHROCYTES; HEMOLYSIS; HUMANS; MICONAZOLE; MICROBIAL SENSITIVITY TESTS; MUCINS; SALIVARY PROTEINS;

EID: 2442719004     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkh181     Document Type: Article

References (46)

1. White, T. C., Marr, K. A. & Bowden, R. A. (1998). Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clinical Microbiology Reviews 11, 382-402.
2. Ellepola, A. N. & Samaranayake, L. P. (2000). Oral candidal infections and antimycotics. Critical Reviews in Oral Biology and Medicine 11, 172-98.
3. Ostrosky-Zeichner, L. & Rex, J. H. (2002). Antifungal prophylaxis: an ounce of prevention is worth three grams of amphotericin B. [Online] http://www.medscape.com (16 March 2004, date last accessed).
4. Patel, R. (1998). Antifungal agents. Part I. Amphotericin B preparations and flucytosine. Mayo Clinic Proceedings 73, 1205-25.
5. Lewis, R. E. & Klepser, M. E. (1999). The changing face of nosocomial candidemia: epidemiology, resistance, and drug therapy. American Journal of Health System Pharmacy 56, 525-33; quiz 534-35.
6. Groll, A. H. & Walsh, T. J. (2002). Antifungal chemotherapy: advances and perspectives. Swiss Medical Weekly 132, 303-11.
7. Hancock, R. E. (1997). Peptide antibiotics. Lancet 349, 418-22.
8. van't Hof, W., Veerman, E. C., Helmerhorst, E. J. et al. (2001). Antimicrobial peptides: properties and applicability. Biological Chemistry 382, 597-619.
9. Yeaman, M. R., Gank, K. D., Bayer, A. S. et al, (2002). Synthetic peptides that exert antimicrobial activities in whole blood and blood-derived matrices. Antimicrobial Agents and Chemotherapy 46, 3883-91.
10. Oppenheim, F. G., Xu, T., McMillian, F. M. et al. (1988). Histatins, a novel family of histidine-rich proteins in human parotid secretion. Isolation, characterization, primary structure, and fungistatic effects on Candida albicans. Journal of Biological Chemistry 263, 7472-7.
11. Xu, T., Levitz, S. M., Diamond, R. D. et al. (11991). Anticandidal activity of major human salivary histatins. Infection and Immunity 59, 2549-54.
12. Tsai, H. & Bobek, L. A. (1997). Human salivary histatin-5 exerts potent fungicidal activity against Cryptococcus neoformans. Biochimica et Biophysica Acta 1336, 367-9.
13. Helmerhorst, E. J., Reijnders, I. M., van't Hof, W. et al. (1999). Amphotericin B- and fluconazole-resistant Candida spp., Aspergillus fumigatus, and other newly emerging pathogenic fungi are susceptible to basic antifungal peptides. Antimicrobial Agents and Chemotherapy 43, 702-4.
14. Rothstein, D. M., Spacciapoli, P., Tran, L. T. et al. (2001). Anticandida activity is retained in P-113, a 12-amino-acid fragment of histatin 5. Antimicrobial Agents and Chemotherapy 45, 1367-73.
15. Tsai, H., & Bobek, L. A. (1998). Human salivary histatins: promising antifungal therapeutic agents. Critical Reviews in Oral Biology and Medicine 9, 480-97.
16. Satyanarayana, J., Situ, H., Narasimhamurthy, S. et al. (2000). Divergent solid-phase synthesis and candidacidal activity of MUC7 D1, a 51-residue histidine-rich N-terminal domain of human salivary mucin MUC7. Journal of Peptide Research 56, 275-82.
17. Bobek, L. A., Mashhoon, S. & Situ, H. (2002). Human salivary MUC7 mucin peptides: effect of size, charge, and cysteine residues on antifungal activity. Journal of Dental Research 81, 236.
18. Bobek, L. A. & Situ, H. (2003). MUC7 20-mer: investigation of antimicrobial activity, secondary structure and possible mechanism of antifungal action. Antimicrobial Agents and Chemotherapy 47, 645-52.
19. Helmerhorst, E. J., Reijnders, I. M., van't Hof, W. et al. (1999). A critical comparison of the hemolytic and fungicidal activities of cationic antimicrobial peptides. FEBS Letters 449, 105-10.
20. Situ, H. & Bobek, L. A. (2000). In vitro assessment of antifungal therapeutic potential of salivary histatin-5, two variants of histatin-5, and salivary mucin (MUC7) domain 1. Antimicrobial Agents and Chemotherapy 44, 1485-93.
21. Kauffman, C. A. & Carver, P. L. (1997). Antifungal agents in the 1990s. Current status and future developments. Drugs 53, 539-49.
22. Vaara, M. & Porro, M. (1996). Group of peptides that act synergistically with hydrophobic antibiotics against gram-negative enteric bacteria. Antimicrobial Agents and Chemotherapy 40, 1801-5.
23. van't Hof, W., Reijnders, I. M., Helmerhorst, E. J. et al. (2000). Synergistic effects of low doses of histatin 5 and its analogues on amphotericin B anti-mycotic activity. Antonie Van Leeuwenhoek 78, 163-9.
24. Franzot, S. P. & Casadevall, A. (1997). Pneumocandin L-743,872 enhances the activities of amphotericin B and fluconazole against Cryptococcus neoformans in vitro. Antimicrobial Agents and Chemotherapy 41, 331-6.
25. Hong, S. Y., Oh, J. E. & Lee, K. H. (1999). In vitro antifungal activity and cytotoxicity of a novel membrane-active peptide. Antimicrobial Agents and Chemotherapy 43, 1704-7.
26. Ueta, E., Tanida, T. & Osaki, T. (2001). A novel bovine lactoferrin peptide, FKCRRWQWRM, suppresses Candida cell growth and activates neutrophils. Journal of Peptide Research 57, 240-9.
27. Lupetti, A., Paulusma-Annema, A., Welling, M. M. et al. (2003). Synergistic activity of the N-terminal peptide of human lactoferrin and fluconazole against Candida species. Antimicrobial Agents and Chemotherapy 47, 262-7.
28. Yan, H. & Hancock, R. E. (2001). Synergistic interactions between mammalian antimicrobial defense peptides. Antimicrobial Agents and Chemotherapy 45, 1558-60.
29. Situ, H., Wei, G., Smith, C. J. et al. (2003). Human salivary MUC7 mucin peptides: effect of size, charge and cysteine residues on antifungal activity. Biochemical Journal 375, 175-82.
30. Helmerhorst, E. J., Van't Hof, W., Veerman, E. C. et al. (1997). Synthetic histatin analogues with broad-spectrum antimicrobial activity. Biochemical Journal 326, 39-45.
31. Ruissen, A. L., Groenink, J., Helmerhorst, E. J. et al. (2001). Effects of histatin 5 and derived peptides on Candida albicans. Biochemical Journal 356, 361-8.
32. Eliopoulos, G. M. & Moellering, T. C. (1996). Antimicrobial combinations. In Antibiotics in Laboratory Medicine, 4th edn (Lorian, V., Ed), pp. 330-96. Williams & Wilkins, Baltimore, MD, USA.
33. Odds, F. C. (2003). Synergy, antagonism, and what the chequerboard puts between them. Journal of Antimicrobial Chemotherapy 52, 1.
34. Hancock, R. E. & Lehrer, R. (1998). Cationic peptides: a new source of antibiotics. Trends in Biotechnology 16, 82-8.
35. Lee, K. H., Hong, S. Y., Oh, J. E. et al. (1998). Identification and characterization of the antimicrobial peptide corresponding to C-terminal beta-sheet domain of tenecin 1, an antibacterial protein of larvae of Tenebrio molitor. Biochemical Journal 334, 99-105.
36. Lupetti, A., Paulusma-Annema, A., Welling, M. M. et al. (2000). Candidacidal activities of human lactoferrin peptides derived from the N terminus. Antimicrobial Agents and Chemotherapy 44, 3257-63.
37. Hamamoto, K., Kida, Y., Zhang, Y. et al. (2002). Antimicrobial activity and stability to proteolysis of small linear cationic peptides with D-amino acid substitutions. Microbiology and Immunology 46, 741-9.
38. Edgerton, M., Koshlukova, S. E., Lo, T. E. et al. (1998). Candidacidal activity of salivary histatins. Identification of a histatin 5-binding protein on Candida albicans. Journal of Biological Chemistry 273, 20438-47.
39. Tossi, A., Sandri, L. & Giangaspero, A. (2000). Amphipathic, alpha-helical antimicrobial peptides. Biopolymers 55, 4-30.
40. Hong, S. Y., Park, T. G. & Lee, K. H. (2001). The effect of charge increase on the specificity and activity of a short antimicrobial peptide. Peptides 22, 1669-74.
41. Nosanchuk, J. D. & Casadevall, A. (1997). Cellular charge of Cryptococcus neoformans: contributions from the capsular polysaccharide, melanin, and monoclonal antibody binding. Infection and Immunity 65, 1836-41.
42. Nibbering, P. H., Danesi, R., van't Wout, J. W. et al. (2002). Antimicrobial peptides: therapeutic potential for the treatment of Candida infections. Expert Opinion on Investigational Drugs 11, 309-18.
43. Helmerhorst, E. J., Breeuwer, P., van't Hof, W. et al. (1999). The cellular target of histatin 5 on Candida albicans is the energized mitochondrion. Journal of Biological Chemistry 274, 7286-91.
44. Tsai, H. & Bobek, L. A. (1997). Studies of the mechanism of human salivary histatin-5 candidacidal activity with histatin-5 variants and azole-sensitive and -resistant Candida species. Antimicrobial Agents and Chemotherapy 41, 2224-8.
45. Lee, D. G., Kim, H. N., Park, Y. et al. (2002). Design of novel analogue peptides with potent antibiotic activity based on the antimicrobial peptide, HP (2-20), derived from N-terminus of Helicobacter pylori ribosomal protein L1. Biochimica et Biophysica Acta 1598, 185-94.
46. Gobbo, M., Biondi, L., Filira, F. et al. (2002). Antimicrobial peptides: synthesis and antibacterial activity of linear and cyclic drosocin and apidaecin 1b analogues. Journal of Medicinal Chemistry 45, 4494-504.